Home → Tests → Total Cholesterol Test

Total Cholesterol Test

⚠️ Update approaching🔬 Evidence: StrongCardiology
Diğer adları: Cholesterol test, TC, Total cholesterol level
⚠️

Discuss your test results with your doctor. This page is for informational purposes only and does not provide a diagnosis.

⚡ Key Facts

• Measures the total cholesterol carried by all lipoproteins (LDL, HDL, VLDL) • Does not distinguish between "good" and "bad" cholesterol on its own • Used as an initial screening parameter and in risk calculators • Should be interpreted alongside LDL, HDL, and triglycerides

🧪 What Does This Test Measure?

The total cholesterol test measures the combined cholesterol content of all lipoproteins in the blood, including LDL, HDL, and VLDL fractions.

📋 Why Is It Ordered?

Ordered as part of the lipid panel for general screening, as input for cardiovascular risk calculators, and for non-HDL cholesterol calculation.

🔧 Preparation

Total cholesterol is measured as part of the lipid panel. Current guidelines accept non-fasting panels as adequate in most situations.

📊 Reference Ranges

General population classification: Desirable: <200 mg/dL (<5.2 mmol/L) Borderline high: 200–239 mg/dL (5.2–6.2 mmol/L) High: ≥240 mg/dL (≥6.2 mmol/L) ⚠️ Should be interpreted alongside LDL, HDL, and triglycerides.

⬆️ High Values

Elevated total cholesterol may be associated with dietary habits, genetic predisposition, hypothyroidism, diabetes, or certain medications. Does not indicate which fraction (LDL or HDL) is elevated.

⬇️ Low Values

Low total cholesterol is often not clinically concerning on its own. Very low levels may occasionally be associated with malnutrition, malabsorption, hyperthyroidism, or liver disease.

⚙️ What Can Affect Results?

Diet, genetic predisposition, body weight, thyroid function, certain medications, pregnancy, and acute illness may affect total cholesterol levels.

🔬 Evidence Summary

Strong evidence: 4 guidelines, 3 meta-analyses, 1 consensus review.

📚 Most Important Studies on This Topic

1

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia

Guideline· Circulation · 2026 · PMID: 41824590

2

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Guideline· European Heart Journal · 2019 · PMID: 31504418

3

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Review· European Heart Journal · 2017 · PMID: 28444290

✅ Key Takeaways

💡

What you learned: Total cholesterol provides an overview but does not distinguish between LDL and HDL. It should always be interpreted alongside the full lipid panel.

⛔

Total cholesterol alone cannot determine cardiovascular risk. LDL, HDL, triglycerides, and clinical context are all needed.

🔬 Sources Used on This Page

8 sources · Most recent publication: 2026
📋
Guideline
Expert society and guideline recommendations
4
sources
📊
Systematic review / meta-analysis
Combined analysis of multiple studies
3
sources
📖
Review
Comprehensive topic evaluation
1
source
Overall assessment: Evidence level for this topic is strong. This page is supported by 4 guidelines, 3 systematic reviews/meta-analysis, 1 review.

📝 Questions to Ask Your Doctor

Be prepared for your appointment. Add questions to your list.

📋 References

[PMID: 41824590] 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 2026.
[PMID: 40878289] 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2025.
[PMID: 31504418] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2019.
[PMID: 30586774] 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 2018.
[PMID: 28444290] Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017.
[PMID: 22607825] Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet, 2012.
[PMID: 21067804] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 2010.
[PMID: 16214597] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 2005.
Last reviewed: 3/31/2026
Next review: 3/31/2027

🔗 Related Topics

🩺 Aterosklerotik kardiyovasküler hastalık🧪 LDL cholesterol🧪 HDL kolesterol🧪 Trigliserid🧪 CRP (Enflamasyon belirteci)
⚖️ This page does not replace medical advice. Make treatment decisions with your doctor.
Content is based on scientific studies indexed in PubMed and current clinical guidelines.